Assessing a New Treatment for Cats with Hypertrophic Cardiomyopathy

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
For questions and more information about this study, please contact the team using the information below.
Study coordinator
Name - Ashley Walker, DVM
Email - alwalker@ucdavis.edu
Phone - (530) 752-1393

Logo Image
"Help us study a new drug that could treat HCM in cats!"
Animal: Cats
Age: 1-12 years
Sex:
Any
Healthy Pets: No
Keywords: cat, hcm, cardiomyopathy, subclinical, hypertrophic cardiomyopathy
Type: Clinical Drug Trial
Investigator:
Background and purpose
The purpose of this clinical trial is to evaluate the effects of a novel drug therapy (rapamycin) in cats with hypertrophic cardiomyopathy (HCM).

Rapamycin has been shown to reverse HCM in rodents and in people – this study will be the first study to evaluate its potential in cats. A small study was conducted in healthy cats to evaluate the drug effects and safety before starting this clinical trial.
What happens in this study

This is a six month clinical trial and consists of four visits in-person, at enrollment, 2 months, 4 months, and six months. The is a drug trial and cats will receive either the study drug (rapamycin) or placebo once weekly by mouth for the entire six months.

Pet owner responsibilities

Pet owners will be responsible for bringing their cat in for each scheduled visit (minimum of four) and administration of the once weekly medication for the six month period.

Participation requirements

Eligible: Cats with HCM that are otherwise healthy. Must be <12 yrs of age and weigh 7.7lbs or more.

Ineligible: Cats with congestive heart failure, hypertension, chronic kidney disease, anemia or other serious illness requiring ongoing medication that alters cardiac function.

To determine eligibility, we will need:

  • Cardiology exam
  • Echocardiogram
  • Chest X-rays
  • Bloodwork
  • Blood pressure measurement
  • Electrocardiogram
Benefits and risks of participating
Initial and recheck cardiology exams, echocardiograms, chest x-rays, bloodwork, blood pressure measurement, and electrocardiograms are all provided at no cost to the client.

Cats enrolled on the study will be under the care of a board-certified cardiologist .

Rapamycin or placebo tablets will be provided for the 6-month treatment period.

Hospital costs up to $1000 if the cat experiences an adverse event or events as a result of taking part in the study and needs medical treatment.
Compensation
All diagnostics performed at each visit will be at no cost to the client.




Trial sponsored by TriviumVet
Resources
Schedule
Study duration and period
Four in-clinic visits will be needed. Once weekly oral administration of medication is required.
Recruitment period
From Jan. 4, 2021
Location
UC Davis Veterinary Medicial Teaching Hospital
1 Garrod Drive
Davis, CA 95616
Contact
Ashley Walker, DVM
Research Topic
Conditions:
  • hypertrophic cardiomyopathy
  • HCM
  • Cat
  • cardiac
  • disease
  • heart

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview